Ponasterone A (Synonyms: 25-Deoxyecdysterone) |
Catalog No.GC44667
One-Click Copy Product Info
|
Ponasterone A is a high-affinity ecdysone receptor agonist, belonging to the plant ecdysteroid class of compounds.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 13408-56-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ponasterone A is a high-affinity ecdysone receptor agonist, belonging to the plant ecdysteroid class of compounds[1-2]. Ponasterone A can serve as an effective modulator of gene expression in cells and transgenic animals, enabling rapid switching on and off of reporter genes[3-4].
In vitro, EcR293 clone-11 sub-1 cells were treated with Ponasterone A (1–10μM) for 3 weeks. Ponasterone A significantly induced iNOS expression, promoted the production of nitric oxide, and upregulated the mRNA expression of Fas and FasL[5]. Human Simpson‑Golabi‑Behmel syndrome adipocytes treated with Ponasterone A (5–50μM), Ponasterone A did not significantly affect lipid accumulation or basal lipolysis, nor did Ponasterone A alter isoproterenol-stimulated lipolysis[6].
In vivo, FVB mice carrying the MMTV-VgEcR/RXRα and (E/GRE)3β-Gal triple transgene were intraperitoneally injected with Ponasterone A (750μg) (either 24 hours after a single injection or via subcutaneous implantation of sustained-release pellets for 10 days). Ponasterone A induced uniform and sustained expression of the β-galactosidase gene in mammary epithelial cells, with no significant tissue toxicity or abnormal mammary development[7]. Tumor-bearing nude mice (with C8161 pVgRXR siGRM1 A13 cells) were treated intraperitoneally with Ponasterone A (10mg/kg) twice weekly (starting when tumor volume reached 10–20mm³, lasting 37–42 days). Ponasterone A significantly inhibited tumor growth, increased the proportion of cleaved Caspase-3-positive cells, and decreased the proportion of Ki-67-positive cells[8].
References:
[1] Hansen KØ, Isaksson J, Glomsaker E, et al. Ecdysteroids from the Arctic Bryozoan Alcyonidium gelatinosum. Molecules. 2018 Jun 19;23(6):1481.
[2] Gu Y, Ihara Y. Evidence that collapsin response mediator protein-2 is involved in the dynamics of microtubules. J Biol Chem. 2000 Jun 16;275(24):17917-20.
[3] Xiao YY, Beilstein MA, Wang MC, et al. Development of a ponasterone A-inducible gene expression system for application in cultured skeletal muscle cells. Int J Biochem Cell Biol. 2003 Jan;35(1):79-85.
[4] McCarthy JF. Ponasterone A: a new ecdysteroid from the embryos and serum of brachyuran crustaceans. Steroids. 1979 Dec;34(7):799-806.
[5] Xu W, Liu L, Charles IG. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J. 2002 Feb;16(2):213-5.
[6] Todorova V, Savova MS, Ivanova S, et al. Anti-Adipogenic Activity of Rhaponticum carthamoides and Its Secondary Metabolites. Nutrients. 2023 Jul 7;15(13):3061.
[7] Albanese C, Reutens AT, Bouzahzah B, et al. Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice. FASEB J. 2000 May;14(7):877-84.
[8] Wangari-Talbot J, Wall BA, Goydos JS, et al. Functional effects of GRM1 suppression in human melanoma cells. Mol Cancer Res. 2012 Nov;10(11):1440-50.
| Cell experiment [1]: | |
Cell lines | EcR293 clone-11 sub-1 human fetal kidney cells (inducible iNOS expression system) |
Preparation Method | EcR293 clone-11 sub-1 cells were maintained in standard culture medium and microencapsulated within a semipermeable alginate-poly-L-lysine membrane. Cells were treated with Ponasterone A at concentrations of 1μM or 10μM for specified durations to induce iNOS expression. |
Reaction Conditions | 1–10μM; time-dependent treatment (up to 3 weeks in vitro) |
Applications | Ponasterone A significantly induced iNOS expression in a dose-dependent manner. Ponasterone A also triggered concomitant upregulation of Fas and FasL mRNA levels, and enhanced NO production comparable to cytokine-activated macrophages. |
| Animal experiment [2]: | |
Animal models | Athymic nude mice bearing human melanoma xenografts |
Preparation Method | Mice were subcutaneously inoculated with C8161 pVgRXR siGRM1 A13 or control cells. When tumor volumes reached 10–20mm³, mice received Ponasterone A (10mg/kg) or vehicle via intraperitoneal injection twice weekly for 37–42 days. |
Dosage form | 10mg/kg; i.p.; twice weekly. |
Applications | Ponasterone A administration significantly suppressed tumor growth, increased cleaved Caspase-3-positive cells, and decreased Ki-67 proliferation marker expression in GRM1-silenced xenografts. |
References: | |
| Cas No. | 13408-56-5 | SDF | |
| Synonyms | 25-Deoxyecdysterone | ||
| Canonical SMILES | O=C1[C@]2([H])C[C@@H](O)[C@@H](O)C[C@]2(C)[C@]3([H])C([C@@](CC[C@]4([H])[C@]([C@H](O)CCC(C)C)(O)C)(O)[C@]4(C)CC3)=C1 | ||
| Formula | C27H44O6 | M.Wt | 464.6 |
| Solubility | DMF: 3 mg/mL,DMSO: 1 mg/mL,Ethanol: 5 mg/mL,Ethanol:PBS (pH 7.2)(1:2): 0.3 mg/mL,Methanol: Soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1524 mL | 10.7619 mL | 21.5239 mL |
| 5 mM | 430.5 μL | 2.1524 mL | 4.3048 mL |
| 10 mM | 215.2 μL | 1.0762 mL | 2.1524 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A Powder
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)